Also in the first quarter, we entered into a broad manufacturing agreement with CordenPharma to support the future commercialization of VK2735. This comprehensive agreement provides access to ...

Viking continued to build on the strong momentum achieved in 2024,” stated Brian Lian, Ph.D., chief executive officer of Viking. “Throughout the first quarter we continued to ramp up activities in ...

SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ: VKTX) reported a wider-than-expected loss for the first quarter of 2025 as research and development expenses increased, but its stock edged up 1% ...